KLK3 and pachyonychia congenita: To predict the risk of disease recurrence following definitive treatment for localized prostate cancer (PC), risk stratification tools often integrate Gleason sum (GS), prostate specific antigen (PSA), and clinical tumor (cT) stage 1, 2, 3.